This meta-analysis, including both single-center and multicenter observational studies, compared the risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis receiving IL-17 inhibitors and those receiving non-biologics. The gene discussed is IL17A; the disease is psoriasis.